Welcome to our dedicated page for Evaxion AS news (Ticker: EVAX), a resource for investors and traders seeking the latest updates and insights on Evaxion AS stock.
Evaxion A/S (NASDAQ: EVAX) is a clinical-stage TechBio company that regularly issues news on its AI-Immunology™ powered vaccine and immunotherapy programs. The company’s updates highlight progress across cancer, infectious disease and autoimmune disease research, making EVAX news relevant for investors and followers of AI-driven biotechnology.
News from Evaxion often covers clinical and preclinical data from its oncology pipeline, including the personalized cancer vaccine EVX-01 for advanced melanoma and the ERV-based off-the-shelf cancer vaccine candidate EVX-04 for acute myeloid leukemia. Releases may detail biomarker findings, immune response data, and presentations at major scientific meetings such as oncology and hematology conferences.
On the infectious disease side, Evaxion publishes updates on vaccine candidates like the gonorrhea program EVX-B2 and the CMV vaccine program EVX-V1. These announcements can include preclinical efficacy data, discovery of novel AI-identified antigens, and progress in optimizing vaccine components such as AI-optimized glycoprotein antigens. Business development news may also describe option decisions, out-licensing arrangements and partnership discussions with pharmaceutical companies.
Corporate and financial communications form another important part of the EVAX news flow. Evaxion reports business updates, financial results, capital raises, changes to its Articles of Association related to share capital, and its financial calendar through press releases and accompanying SEC Form 6-K filings. The company also issues announcements about strategic milestones, such as expanding AI-Immunology™ into autoimmune diseases or enhancing the platform with automated vaccine design modules.
This news page aggregates these items so readers can follow Evaxion’s scientific progress, platform evolution, partnership activity and corporate developments in one place. For those tracking AI-based drug discovery, cancer vaccines and infectious disease vaccines, the EVAX news feed provides ongoing insight into how Evaxion applies its AI-Immunology™ platform across multiple therapeutic areas.
Evaxion Biotech reported encouraging clinical progress in Q2 2021, with strong data from its EVX-01 and EVX-02 programs leading to planned Phase 2b trials. EVX-01 demonstrated a 67% patient benefit rate when combined with anti-PD-1 treatment for metastatic melanoma, outperforming historical rates of 40%. The company holds $18.8 million in cash, sufficient to fund its key programs into 2022. Additionally, Evaxion's RAVEN AI platform shows promise in vaccine design targeting coronavirus variants.
Evaxion Biotech (NASDAQ: EVAX) reported promising results from its Phase 1/2a trial of EVX-01 in metastatic melanoma. The therapy, combined with anti-PD1 treatment, resulted in a 67% Objective Response Rate (ORR), with 22% achieving complete responses and 44% partial responses. The study demonstrated a favorable safety profile, noting only Grade 1 and 2 adverse events. The company plans to advance EVX-01 into a Phase 2 trial by December 2021 and has generated data from the EVX-02 trial, showing T-cell activation. Overall, these findings support the innovative AI-Immunology platform, PIONEER.
Evaxion Biotech (NASDAQ: EVAX) announced a conference call on July 8, 2021, to discuss the Phase 1/2a data for its products EVX-01 and EVX-02. The call will feature CEO Lars Wegner, CFO Glenn Vraniak, and co-founder CBO Niels Iversen Moller, starting at 8:00 a.m. EDT. This event will provide insights on Evaxion's AI-driven immunotherapy development efforts for cancer and other diseases. The results are crucial for evaluating the company's growth potential and product pipeline. A live webcast will be available on Evaxion's Investor Relations page.
Evaxion Biotech (Nasdaq: EVAX) announced the acceptance of a scientific paper at ICML 2021. The paper, titled “Efficient Generative Modelling of Protein Structure Fragments using a Deep Markov Model,” presents BIFROST, a predictive system that converts sequence data into protein structure information, aiding drug and vaccine design. BIFROST's Bayesian approach improves the reliability of predictions, making it suitable for drug development with incomplete datasets. The company aims to integrate these advancements into its AI platforms for enhanced vaccine development.
Evaxion Biotech A/S (NASDAQ: EVAX) announced new preclinical data from its AICoV program, aimed at developing next-generation vaccines against coronaviruses. Utilizing the RAVEN AI platform, the program identifies novel immunogenic T cell epitopes beyond the spike protein, enhancing vaccine design against variants. Key advantages include overcoming variant effectiveness issues and eliminating cold storage needs. Initial animal studies showed promising immune responses comparable to human sera. The AICoV initiative receives support from international investors and Innovation Fund Denmark.
Evaxion Biotech (NASDAQ: EVAX) announced the election of Lars Holtug to its Board of Directors during the Annual General Meeting on May 25, 2021. Holtug, a seasoned financial professional with extensive experience in the healthcare sector, will chair the Audit Committee, succeeding Helen M. Boudreau. Chairwoman Marianne Søgaard expressed confidence that Holtug's background in the biotech industry and his past roles, including at PwC, will be beneficial as Evaxion progresses its clinical programs targeting cancer and infectious diseases.
Evaxion Biotech A/S (NASDAQ: EVAX) announced its Q1 2021 financial results, reporting cash reserves of $27 million as of March 31, 2021. Following a successful IPO raising $30 million, Evaxion is advancing its lead product candidates, EVX-01 and EVX-02, with Phase 1/2a data expected late Q2 2021. R&D expenses increased to $3.9 million, reflecting growth in clinical trials and staffing. The company reported a net loss of $4.1 million for the quarter. Overall, the financial position supports continued development of key programs and a cash runway extending into 2022.
Evaxion Biotech (NASDAQ: EVAX) will present its Q1 2021 financial results on May 13, 2021. CEO Lars Wegner and CFO Glenn Vraniak will lead an earnings call at 8:30 a.m. EDT. Dial-in numbers: US: 877-407-0792, International: +1-201-689-8263, Conference ID: 13718732. An audio webcast will be available on Evaxion's website. The company develops AI-driven immunotherapies targeting cancer and infectious diseases, with a pipeline including three patient-specific cancer treatments currently in Phase 1/2a trials.
Evaxion Biotech (Nasdaq: EVAX) announced a significant presentation by Dr. Jens Kringelum at the 4th Neoantigen Summit Europe, focusing on AI's role in personalized cancer medicine. The discussion highlighted advancements in predicting cancer neoepitopes using peptide-MHC complex stability. Evaxion's AI platform, PIONEER, is continuously evolving, leveraging new methods for enhanced immunotherapy design. CEO Lars Wegner emphasized the efficiency gains in drug development from these improvements. The company is developing a range of patient-specific immunotherapies and vaccines to address bacterial and viral infections.
Evaxion Biotech A/S (Nasdaq: EVAX) reported strong progress in its Q4 and full year 2020 results, highlighted by a successful IPO in February 2021 that raised $30 million. The company has cash reserves of $5.8 million as of Dec 31, 2020, which have been bolstered by IPO proceeds, ensuring funding into 2022. Clinical trials for their cancer vaccine EVX-02 are on track, with anticipated data releases in Q2 2021. However, the company reported a net loss of $15 million for 2020 with increased R&D and administrative expenses compared to the previous year.